01 Apr 2020
Development by UCL-led group with Oxford Optronix can cut Covid-19 patient need for intensive care beds.
The breathing aid, known as Continuous Positive Airway Pressure (CPAP), has been used extensively in hospitals in Italy and China to help Covid-19 patients with serious lung infections to breathe more easily, when oxygen alone is insufficient. A significant component of the device is an optical oxygen monitor developed in just five days by UK manufacturer Oxford Optronix.
CPAP machines are routinely used by the NHS to support patients in hospital or at home with breathing difficulties. They work by pushing an air-oxygen mix into the mouth and nose at a continuous rate, keeping airways open and increasing the amount of oxygen entering the lungs. Invasive ventilators deliver breaths directly into the lungs, but require heavy sedation and connection to a tube placed into the patient’s trachea.
Since Wednesday 18th March, engineers at UCL and HPP and clinicians at UCLH have been working round the clock at UCL’s engineering hub MechSpace to reverse-engineer a device that can be produced rapidly by the thousands. This has now been recommended for use by the UK’s Medicines and Healthcare products Regulatory Agency.
This breathing aid was produced within a rapid timeframe – it took less than 100 hours from the initial meeting to production of the first device. One hundred devices are to be delivered to UCLH for clinical trials, with rapid roll-out to hospitals around the country ahead of the predicted surge in Covid-19 hospital admissions.
The collaboration, supported by the National Institute for Health Research UCLH Biomedical Research Centre, demonstrates the way that universities, the NHS and industry are coming together to help the national response to the Covid-19 coronavirus outbreak, by providing vital technologies to the NHS which can enable them to care for patients who require respiratory support.Professor Mervyn Singer said, “These devices will help to save lives by ensuring that ventilators, a limited resource, are used only for the most severely ill. While they will be tested at UCLH first, we hope they will make a real difference to hospitals across the UK by reducing demand on intensive care staff and beds, as well as helping patients recover without the need for more invasive ventilation.”
Professor Rebecca Shipley, Director of UCL Institute of Healthcare Engineering, said: “At UCL, we have an established ecosystem of partnerships spanning engineers, healthcare and industry ready to be mobilized in times of need. It’s been a privilege to work closely with our clinical colleagues and with doctors leading the Covid-19 response in China and Italy. This close contact has helped us to define the need and respond with technology that we hope will support the NHS in the weeks and months to come.”
Professor Tim Baker (UCL Mechanical Engineering) said, “From being given the brief, we worked all hours of the day, disassembling and analyzing an off-patent device. Using computer simulations, we improved the device further to create a state-of-the-art version suited to mass production. We were privileged to be able to call on the capability of Formula One – a collaboration made possible by the close links between UCL Mechanical Engineering and HPP.”
Professor David Lomas (UCL Vice Provost, Health) said, “This breakthrough has the potential to save many lives and allow our frontline NHS staff to keep patients off ventilators. I would like to pay tribute to the incredible team of engineers and clinicians at UCL, HPP and UCLH, for working round-the-clock to develop this new prototype. It shows what can be done when universities, industry and hospitals join forces for the national good.”
Andy Cowell, Managing Director of Mercedes-AMG High Performance Powertrains, said, “The Formula One community has shown an impressive response to the call for support, coming together in the ‘Project Pitlane’ collective to support the national need at this time across a number of different projects.”
Andy Obeid, Chief Executive of Oxford Optronix, which is manufacturing the oxygen monitors for the CPAP devices, said, “By working flat out and mobilizing the support of every individual in my company as well as other small companies across the UK, we have accomplished something in five days that would normally take two years. The bedside monitor will continuously measure the concentration of oxygen being delivered to the patient and is now ready for clinical trials.”